A new 5.9% passive stake from Goldman Sachs signals institutional interest following TNDM's improving earnings trajectory. Monitor for any subsequent 13D conversion or further accumulation, though the passive certification makes activist intent unlikely. The stake size is notable but not transformative for a $1.2B market cap company.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $18.71entry
- T+1 · 6d ago +0.32%α −1.00% · $18.77
- T+4 · todayOpen
- T+5 · in 3h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Goldman Sachs Group disclosed a 5.9% passive stake in Tandem Diabetes Care as of September 30, 2026, holding approximately 4.09 million shares. This is a new 13G filing by Goldman Sachs, which had not previously reported a 5%+ position in TNDM. The filing comes shortly after Tandem's Q3 2026 earnings beat consensus estimates, with revenue up 14% YoY and a narrower operating loss.
Key Financial Metrics
Key Facts
- Goldman Sachs Group reported beneficial ownership of 4,091,935 shares of Tandem Diabetes Care common stock, representing 5.9% of shares outstanding as of September 30, 2026.
- The filing is a Schedule 13G, certifying passive intent with no purpose or effect of changing or influencing control of the issuer.
- Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser, is the direct holder; Goldman Sachs Group is the parent holding company.
- This is a new 13G filing by Goldman Sachs; no prior 13G or 13D from this filer appears in the cross-filing context.
- Tandem Diabetes Care recently reported Q3 2026 sales of $283.7M (+14% YoY), beating consensus, and a GAAP net loss of -$0.10 per share, also beating the -$0.24 consensus estimate.
Financial Impact
Goldman Sachs holds approximately 4.09 million shares, valued at roughly $70M based on the $1.2B market cap and 5.9% stake.
Risk Factors
- Goldman Sachs may reduce the position in future quarters without prior notice, as 13G filers are not required to disclose dispositions below the 5% threshold.
- The stake is held across multiple operating units with potential disaggregation; actual economic exposure may differ from the reported 5.9%.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000886982-26-000595 |
| Document: 0000886982-26-000595-index-headers.html | 0000886982-26-000595 |
| Document: 0000886982-26-000595-index.html | 0000886982-26-000595 |
| Document: 0000886982-26-000595.txt | 0000886982-26-000595 |
Track record
9 reports on TNDM
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $18.50 Now $18.48 +0.11% settles Nov 18
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $20.00 Now $18.48 −7.60% settles Nov 17
- Nov 13, 20263d ago 8-K Bullish 5/10 Entry $20.07 to $18.48 Now $18.48 −7.92% ▼ −7.92% −6.01% vs SPY
- Nov 9, 20267d ago SC 13G Neutral 4/10 Viewing Entry $18.71 to $18.77 Now $18.48 −1.23% ▲ +0.32% −1.00% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $16.91 to $18.17 Now $18.48 +9.28% ▲ +7.45% +5.08% vs SPY
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $19.68 to $19.79 Now $18.48 −6.10% ▲ +0.56% +0.94% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $15.80 to $16.60 Now $18.48 +16.96% ▲ +5.06% +4.52% vs SPY
- May 15, 202626w ago 8-K Neutral 3/10 Entry $12.82 to $13.53 Now $18.48 +44.15% ▲ +5.54% +5.60% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $19.35 to $19.68 Now $18.48 −4.50% ▲ +1.71% +1.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers